作者: Miguel Angel Pavón , Matilde Parreño , Marta Téllez-Gabriel , Xavier León , Irene Arroyo-Solera
DOI: 10.1002/HED.24232
关键词: Nuclear receptor coactivator 1 、 Internal medicine 、 Head and neck cancer 、 Immunohistochemistry 、 Cohort 、 Creatine kinase 、 Chemotherapy 、 Disease 、 Medicine 、 Head and neck squamous-cell carcinoma 、 Pathology 、 Oncology
摘要: Background We studied the association between expression of a subset previously identified genes and clinical outcome in patients with head neck cancer. Methods We analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) 89 tumor biopsies from stage III to IVa/b chemotherapy treated (n = 46). Two additional cohorts RNAseq (The Cancer Genome Atlas [TCGA] project; n = 371) or immunohistochemistry (IHC; n = 73) were used validate results. Results Thirty associated local-recurrence progression-free survival. The best multi-gene decision-tree model predict local recurrence included nuclear receptor coactivator 1 (NCOA1) serum-amyloid A2 (SAA2) expression, whereas disease creatine kinase mitochondrial (CKMT1) metal-regulatory transcription factor (MTF1). Both models cancer-specific Results confirmed analyzing data TCGA project. CKMT1 NCOA1 as independent risk factors for survival an cohort immunohistochemistry. Conclusion CKMT1 has prognostic significance advanced-stage carcinoma. © 2015 Wiley Periodicals, Inc. Head Neck,